2 January 2025 in F1000Research
Background Anti-viral therapy is not routinely recommended for chronic hepatitis B virus (HBV) infection, in patients who have persistently elevated serum HBV DNA level (>2000 IU/mL), normal alanine aminotransferase (ALAT) and without significant liver fibrosis, defining the indeterminate phase. The objective of the study is to identify the factors associated with the progression of liver fibrosis in chronic HBV infected patients in the indeterminate phase. Methods This is cross-sectional study, conducted in Infectious Disease and Hepato-gastroenterology departments of Farhat Hached university hospital, between January 2008 and January 2022. We have included the Ag HBs (+) patients initially not treated, presenting at the time of the initial evaluation: a viral load> 2,000 IU/L for at least six months, normal ALAT (<40UI) and a fibrosis score F0 and/or F1 (in liverbiopsy or FibroScan). Univariate and logisticreg ression analysis were performed to identify the factors associated with liver fibrosis progression. Results In total, 97 patients were included, with a median age of 32.9± 9.1 years, and a female predominance (sex ratio M/F=0.64). Progression of fibrosis was observed in 16 patients (16.5%) with a mean delay of 70.9±41.1 months. In the univariate analysis, factors associated with progression of fibrosis were the presence of comorbidities (p=0.001), the high initial viral load (p=0.004), the appearance of cytolysis (p=0.001) and the increase in viral load (p=0.002), during follow-up. The AUROC of the initial viral load was 0.664 (95%CI: 0.500-0.820). An intial viral load at 8090 UI/l was associated with the progression of fibrosis with a sensibility of 70.3% and specificity of 63%. Conclusion Factors associated with progression of fibrosis in the indeterminate phase of chronic HBV infection were the presence of comorbidities, and changes of ALAT during follow-up. This leads us to consider extending the therapeutic indications to this group of patients.
31 December 2023 in The Journal of Infection in Developing Countries
Introduction: The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has resulted in around 1 million COVID-19 infection cases and over 29,000 deaths in Tunisia thus far. There is great variability in the prevalence of asthma among patients with COVID-19, but the impact of asthma on patients with COVID-19 is not clear. We sought to describe the clinical features of Tunisian patients with COVID-19 and to compare asthmatic and non-asthmatic patients. Methodology: This retrospective study included 675 Tunisian patients who were hospitalized with COVID-19. Clinical characteristics were collected from medical records. Bivariate analyses and multivariate regression models were used to assess the associations between asthma and the risk of severe symptoms, including death/recovery. Results: The prevalence of asthma in the sample was 14.5%. The results show that asthmatic patients with COVID-19 have significantly less severe symptoms and better outcomes than non-asthmatic patients. Conclusions: Asthma was not found to be associated with higher severity or worse prognosis among patients with COVID-19 in Tunisia.
11 December 2025 in Libyan Journal of Medicine
Formal training for residents-as-teachers is increasingly emphasized in many institutions worldwide. This study investigated 'residents-as-teachers' training, perceptions, and practices at the Faculty of Medicine of Sousse. An online survey was sent to the residents of FMSo (n = 1060). The three assessed areas in the survey were: training and teaching experience, teaching practices used, and attitudes and perceptions. Statistical analyses included descriptive statistics, two-proportion tests, and multivariate logistic regression. One hundred five residents responded (response rate: 9.9%). Although 68.6% reported teaching weekly (often 1-5 hours), and 33.3% found it enjoyable or rewarding, a notable feedback gap existed: 17.1% received no feedback from supervisors, and 15.2% none from learners. Preferred teaching methods included clinical case discussions (40.9%), role-playing (38.0%), brainstorming (37.1%), and workshops (35.2%). Multivariate analysis showed residency year was the only predictor of teaching contribution (OR = 3.72; p< 0.001). Despite limitations like the low response rate, the study concludes that residents value teaching but lack adequate feedback. It underscores the critical need to develop new and refine existing training programs for residents-as-teachers to improve the overall quality of medical education.
19 May 2025 in F1000Research
Background Antiviral therapy is not routinely recommended for chronic hepatitis B virus (HBV) infection in patients exhibiting persistently elevated serum HBV DNA levels (>2000 IU/mL), normal alanine aminotransferase (ALT), and without significant liver fibrosis – a clinical state termed the indeterminate phase. Recognizing the evolving treatment landscape, this study aimed to identify factors associated with liver fibrosis progression in chronic HBV patients within this indeterminate phase. Methods This retrospective longitudinal cohort study was conducted in the Infectious Disease and Hepato-gastroenterology departments of Farhat Hached University Hospital in Sousse, Tunisia, between January 2008 and January 2022. We included HBsAg-positive patients initially untreated, presenting at evaluation with a viral load >2,000 IU/mL for at least six months, normal ALT (<40 IU/L), and a fibrosis score of F0 and/or F1 (determined by liver biopsy or FibroScan). Univariate and logistic regression analyses were performed to identify factors associated with liver fibrosis progression. Results A total of 97 patients were included, with a median age of 32.9 ± 9.1 years, and a female predominance (M/F ratio = 0.64). Fibrosis progression was observed in 16 patients (16.5%), with a mean delay of 70.9 ± 41.1 months. Univariate analysis revealed associations between fibrosis progression and the presence of comorbidities (p=0.001), a high initial viral load (p=0.004), elevated liver enzymes (p=0.001), and an increase in viral load during follow-up (p=0.002). Multivariate analysis identified comorbidities (p<0.001) and changes in ALT levels (p<0.001) as independent predictors of fibrosis progression. The AUROC of the initial viral load was 0.664 (95%CI: 0.500-0.820). Conclusion The presence of comorbidities and changes in ALT levels during follow-up were associated with fibrosis progression in the indeterminate phase of chronic HBV infection. These findings suggest a potential rationale for extending therapeutic indications to include this patient population.
27 August 2025 in F1000Research
Background: Antiviral therapy is not routinely recommended for chronic hepatitis B virus (HBV) infection in patients with elevated serum HBV DNA levels (>2000 IU/mL), normal alanine aminotransferase (ALT) levels, and no significant liver fibrosis, referred to as the “indeterminate phase.” This study aimed to identify factors associated with liver fibrosis progression in chronic HBV patients within this phase. Since the study’s design, hepatitis B treatment guidelines have undergone significant evolution. New WHO recommendations published in 2024 advocate for expanded treatment criteria, making terms like “Indeterminate phase” obsolete. Methods This retrospective longitudinal cohort study was conducted at Farhat Hached University Hospital in Sousse, Tunisia, from January 2008 to January 2022. We included HBsAg-positive patients who were untreated, had a viral load >2,000 IU/mL for at least six months, normal ALT (<40 IU/L), and a fibrosis score of F0 and/or F1 (determined by liver biopsy or FibroScan). Univariate and logistic regression analyses were performed to identify factors associated with liver fibrosis progression. Results A total of 97 patients were included, with a median age of 32.9 ± 9.1 years and a female predominance (M/F ratio = 0.64). Fibrosis progression occurred in 16 patients (16.5%), with a mean delay of 70.9 ± 41.1 months. Univariate analysis showed significant associations between fibrosis progression and comorbidities (p = 0.001), high initial viral load (p = 0.004), elevated liver enzymes (p = 0.001), and increased viral load during follow-up (p = 0.002). Multivariate analysis identified comorbidities (p<0.001) and changes in ALT levels (p<0.001) as independent predictors of fibrosis progression. Conclusion Comorbidities and changes in ALT levels during follow-up were associated with fibrosis progression in the indeterminate phase of chronic HBV infection. Our findings support recent changes in international guidelines, including those from the WHO in 2024, which expand therapeutic indications for individuals living with hepatitis B.